{"hands_on_practices": [{"introduction": "To truly understand C-type lectin receptor signaling, we must be able to dissect the function of each component. This practice explores the classic molecular biology strategy of creating chimeric receptors to test the principles of sufficiency and necessity. By swapping the cytoplasmic tails between activating (ITAM-associated) and inhibitory (ITIM-associated) receptors, we can rigorously determine whether the information encoded in the tail is sufficient to dictate the cell's response, a foundational concept in receptor biology [@problem_id:2838135].", "problem": "A C-type lectin receptor is a membrane protein with an extracellular carbohydrate recognition domain, a transmembrane segment, and a cytoplasmic tail that can encode signaling motifs. In myeloid cells, Immunoreceptor Tyrosine-based Activation Motif (ITAM) and Immunoreceptor Tyrosine-based Inhibition Motif (ITIM) are canonical motifs that, when phosphorylated, recruit Src homology two domain-containing effectors to drive activation or inhibition, respectively. The well-tested facts relevant here are: (i) a canonical ITAM consists of two tyrosines within a YxxL or YxxI context separated by approximately six to eight residues; phosphorylation of both tyrosines enables high-affinity binding of the tandem Src homology two domains of Spleen tyrosine kinase (Syk), leading to activation of Nuclear Factor kappa-B (NF-κB) and Mitogen-Activated Protein Kinase (MAPK) pathways; (ii) a canonical ITIM has the consensus I or V or L or S followed by any residue, then a tyrosine, then any two residues, then I or V or L; phosphorylation of the tyrosine recruits SHP-1 and SHP-2 or SHIP-1 to attenuate activation; (iii) Dectin-1 (Clec7a) is an ITAM-associated C-type lectin receptor that carries a cytoplasmic hemITAM (a single YxxL motif) capable of binding Syk when appropriately phosphorylated as a dimer; (iv) Dendritic cell immunoreceptor (DCIR, Clec4a) is a C-type lectin receptor with a cytoplasmic ITIM that recruits SHP-1 and SHP-2 upon phosphorylation to inhibit activation.\n\nYou are tasked with choosing a single experimental design that most rigorously tests both sufficiency and necessity of cytoplasmic tail motifs for signaling output by swapping tails between an ITAM-associated C-type lectin receptor and an ITIM C-type lectin receptor, while isolating the role of the cytoplasmic motifs from confounding variables such as ligand affinity, receptor clustering avidity, and adaptor usage. The design must allow inference of the following logical statements about signaling output, denoted by $S$: (a) sufficiency: replacing the native tail with a heterologous motif is sufficient to switch the sign and dominant pathway of $S$ under identical ligand engagement and clustering; (b) necessity: mutation of the critical tyrosine(s) in the motif abolishes the switched effect on $S$.\n\nPick the best option.\n\nA. Build chimeras using the Dectin-1 extracellular and transmembrane regions as a constant ligand-binding scaffold fused to either the native Dectin-1 hemITAM tail or the DCIR ITIM tail. In parallel, generate point mutants where the tyrosine in the hemITAM (YxxL) or ITIM is mutated to phenylalanine ($Y \\to F$), rendering the motif non-phosphorylatable. Express all constructs at matched surface levels in myeloid cells lacking endogenous Dectin-1 and DCIR. Stimulate with a single Dectin-1 ligand or with anti-epitope antibody crosslinking to equalize clustering. Quantify NF-κB reporter activity and proinflammatory cytokines, Syk recruitment and phosphorylation, and SHP-1 or SHP-2 co-immunoprecipitation. Interpret sufficiency if the ITIM-tailed chimera reduces $S$ and recruits phosphatases relative to the hemITAM-tailed receptor under identical ligand engagement, and interpret necessity if the $Y \\to F$ mutations abrogate these effects.\n\nB. Swap both extracellular domains and cytoplasmic tails between Mincle and DCIR, stimulate each chimera with its cognate ligand, and read out tumor necrosis factor alpha alone. Do not introduce tyrosine mutations and do not control for adaptor usage or surface expression, since the distinct ligands and native receptor contexts will reveal the intrinsic capacity of each receptor to activate or inhibit.\n\nC. Use Dectin-2, which signals via the ITAM-containing Fc receptor gamma chain, and exchange its minimal cytoplasmic tail with the DCIR ITIM tail. Co-express or omit the Fc receptor gamma chain as needed. Stimulate with a Dectin-2 ligand and read out NF-κB. Conclude sufficiency from any decrease in $S$ upon adding the DCIR tail and necessity from failure to signal when the Fc receptor gamma chain is not co-expressed.\n\nD. Fuse the isolated cytoplasmic tails of Dectin-1 or DCIR directly to a generic membrane anchor lacking an extracellular domain, crosslink with antibody to induce phosphorylation, and measure cyclic adenosine monophosphate levels. Interpret sufficiency if the DCIR tail reduces cyclic adenosine monophosphate relative to the Dectin-1 tail; necessity is inferred if tyrosine to phenylalanine mutations fail to change cyclic adenosine monophosphate.\n\nWhich design most cleanly tests both sufficiency and necessity of the motifs while isolating cytoplasmic information content as the decisive variable for $S$?", "solution": "The problem statement is subjected to validation. The givens are: a set of definitions for C-type lectin receptors (CLRs), their signaling motifs Immunoreceptor Tyrosine-based Activation Motif (ITAM) and Immunoreceptor Tyrosine-based Inhibition Motif (ITIM), and the signaling pathways they engage. Specific examples are provided: Dectin-1 as a hemITAM-bearing receptor and Dendritic cell immunoreceptor (DCIR) as an ITIM-bearing receptor. The objective is to select the most rigorous experimental design to test the sufficiency and necessity of these cytoplasmic motifs for determining the signaling output, denoted as $S$. Sufficiency is defined as the ability of a swapped motif to switch the signal's character. Necessity is defined as the abolition of this switched effect upon mutation of the motif's critical tyrosine(s). The design must control for confounding variables such as ligand affinity and receptor clustering.\n\nThe problem statement is scientifically grounded, well-posed, and objective. It is based on established principles of molecular immunology and describes feasible experimental techniques. The definitions and objectives are precise and internally consistent. Therefore, the problem is valid, and we proceed to analyze the proposed solutions.\n\nThe analysis will evaluate each option against the following criteria derived from the problem statement:\n1.  Correctly tests sufficiency: Does swapping a cytoplasmic tail from an inhibitory to an activating receptor context (or vice-versa) switch the signaling output $S$?\n2.  Correctly tests necessity: Does a point mutation of the critical tyrosine(s) in the swapped tail, for instance a $Y \\to F$ mutation, abrogate the observed switch in signaling?\n3.  Rigorous experimental control: Is the experiment designed to isolate the function of the cytoplasmic tail from confounding variables, including but not limited to ligand-binding characteristics, receptor surface density, and baseline cellular context?\n4.  Appropriate measurements: Are the chosen readouts mechanistically relevant to the signaling pathways under investigation (ITAM/ITIM pathways)?\n\nOption A: This option proposes the construction of chimeric receptors using the Dectin-1 extracellular and transmembrane domains as a constant scaffold. This scaffold is fused to either its native Dectin-1 (hemITAM) tail or the heterologous DCIR (ITIM) tail. This design directly addresses the tail-swapping requirement. The proposal to generate parallel constructs with tyrosine-to-phenylalanine ($Y \\to F$) mutations in both the hemITAM and ITIM motifs provides the correct tool to test necessity, as a $Y \\to F$ substitution prevents phosphorylation and hence motif function. The use of a myeloid cell line lacking endogenous Dectin-1 and DCIR is a critical control to eliminate background signaling. Matching the surface expression levels of all constructs is another essential control, as receptor concentration directly impacts signal strength. Stimulation with a single ligand or crosslinking antibody ensures that the initial stimulus is identical for all constructs, thereby isolating the cytoplasmic tail as the sole independent variable. The proposed readouts are comprehensive and mechanistically appropriate: NF-κB activity and cytokines are canonical distal outcomes of ITAM signaling, while co-immunoprecipitation of Syk (for activation) and SHP-1/SHP-2 (for inhibition) provides direct, proximal evidence of the underlying pathway engagement. The interpretation logic for sufficiency (ITIM tail reduces $S$) and necessity ($Y \\to F$ mutation abrogates the effect) is correct.\nVerdict: **Correct**. This design is methodologically rigorous, includes all necessary controls, and correctly addresses both sufficiency and necessity.\n\nOption B: This design proposes swapping domains between Mincle and DCIR and stimulating each chimera with its own cognate ligand. This approach is fundamentally flawed. Using distinct ligands for different constructs introduces a massive confounding variable; differences in signaling output $S$ cannot be uniquely attributed to the cytoplasmic tail, as they could arise from differences in ligand affinity, receptor clustering dynamics, or off-target effects of the ligands. The proposal to not control for surface expression is a second major error in experimental design. Furthermore, the design omits tyrosine mutations, making it impossible to test for necessity as defined in the problem. Measuring only a single distal cytokine (TNF-α) provides limited mechanistic insight. The rationale provided is antithetical to good scientific practice, which seeks to isolate variables, not conflate them.\nVerdict: **Incorrect**. This design is rife with confounding variables and fails to test necessity.\n\nOption C: This design uses Dectin-2, a receptor that signals through an associated ITAM-containing adaptor protein, the Fc receptor gamma chain (FcRγ). It proposes to swap the Dectin-2 tail with the DCIR ITIM tail. This introduces unnecessary complexity. The central question is about the intrinsic information content of the tails, which is best tested in a simple \"one-component\" receptor system like Dectin-1, not a \"two-component\" system like Dectin-2/FcRγ. The most critical flaw lies in its test for necessity: \"conclude necessity from failure to signal when the Fc receptor gamma chain is not co-expressed\". This is a test for the necessity of the FcRγ adaptor for Dectin-2 signaling, which is an entirely different question. It does not test the necessity of the tyrosine residue within the DCIR ITIM for its inhibitory function. The design fails to include the required $Y \\to F$ mutation.\nVerdict: **Incorrect**. This design misinterprets and fails to test the \"necessity\" criterion as specified by the problem.\n\nOption D: This design proposes to fuse the isolated cytoplasmic tails to a generic membrane anchor, which is a valid strategy for isolating tail function. However, the design suffers from two fatal flaws. First, the proposed readout is cyclic adenosine monophosphate (cAMP). The problem explicitly states that ITAM signaling leads to NF-κB and MAPK activation, and ITIMs recruit phosphatases like SHP-1/SHP-2 and SHIP-1 to attenuate these pathways. While crosstalk with cAMP can exist, it is not the direct or canonical output, and measuring it is inappropriate for testing the primary function of these motifs. Second, the logical framing of the necessity test is incorrect: \"necessity is inferred if tyrosine to phenylalanine mutations fail to change cyclic adenosine monophosphate\". To demonstrate necessity, the mutation must *abrogate* the effect of the motif—that is, it must revert the signaling output to a baseline or opposite state. Stating that the mutation causes no change is the definition of a failed necessity test, not a successful one.\nVerdict: **Incorrect**. This design uses an inappropriate readout and is based on a logically flawed understanding of the necessity criterion.\n\nIn conclusion, only Option A presents a comprehensive, rigorous, and logically sound experimental plan that addresses all requirements set forth in the problem statement. It flawlessly isolates the variable of interest and employs the correct controls and readouts to unambiguously test both sufficiency and necessity.", "answer": "$$\\boxed{A}$$", "id": "2838135"}, {"introduction": "Once we establish the key role of signaling motifs, the next challenge is to map the sequence of events they trigger. This exercise introduces the powerful logic of genetic epistasis, a cornerstone of pathway analysis, to determine the functional order of downstream signaling molecules. Using a hypothetical scenario involving modern CRISPR-Cas9 technology, you will deduce the linear hierarchy of the Syk, CARD9, and MALT1 proteins in the Dectin-1 pathway, learning how to distinguish a specific signaling defect from a general cellular impairment [@problem_id:2838106].", "problem": "A C-type lectin receptor (CLR) such as Dectin-1 on myeloid cells signals through a hem-immunoreceptor tyrosine-based activation motif (hemITAM) that recruits Spleen tyrosine kinase (Syk), leading to assembly of the Caspase Recruitment Domain containing protein 9 (CARD9)–B-cell lymphoma/leukemia 10 (Bcl10)–Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) scaffold, activation of Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB), and induction of tumor necrosis factor (TNF). You are tasked with mapping the order of function of Syk, CARD9, and MALT1 in CLR-induced TNF production using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) knockouts in a human monocyte-like cell line.\n\nUse only the following foundational bases:\n- Core definition of a linear signaling pathway: a proximal receptor-proximal kinase triggers downstream scaffolds and effectors that converge on transcriptional activation.\n- The principle of genetic epistasis in a linear pathway: if gene $X$ acts upstream of gene $Y$, then the double mutant $X^{-/-};Y^{-/-}$ exhibits the phenotype of $Y^{-/-}$ under a stimulus that requires the $X \\to Y$ pathway.\n- The Central Dogma (DNA $\\to$ RNA $\\to$ protein) linking signaling to transcription and translation of TNF.\n\nYou will stimulate cells with a selective Dectin-1 agonist to trigger CLR signaling and quantify TNF output. Appropriate controls must distinguish pathway specificity from global defects.\n\nWhich option most correctly specifies a CRISPR-based genetic epistasis experiment and a pattern of outcomes that would let you infer the order Syk $\\to$ CARD9 $\\to$ MALT1 in CLR-induced TNF production?\n\nA. Create single knockouts Syk$^{-/-}$, CARD9$^{-/-}$, and MALT1$^{-/-}$, and double knockouts Syk$^{-/-}$;CARD9$^{-/-}$, Syk$^{-/-}$;MALT1$^{-/-}$, and CARD9$^{-/-}$;MALT1^{-/-}$ in the same parental background. Stimulate with curdlan at $100\\,\\mu\\text{g}/\\text{mL}$ for $6$ hours and quantify secreted TNF by enzyme-linked immunosorbent assay (ELISA), normalizing to wild-type set at $100\\%$. Include lipopolysaccharide (LPS, Toll-like receptor $4$ ligand, $100\\,\\text{ng}/\\text{mL}$) as a pathway specificity control. Predicted pattern under curdlan: each single knockout markedly reduces TNF (e.g., Syk $\\approx 10\\%$, CARD9 $\\approx 5\\%$, MALT1 $\\approx 5\\%$). Any double knockout that includes MALT1 equals MALT1$^{-/-}$ (approximately $\\approx 5\\%$), and Syk$^{-/-}$;CARD9^{-/-}$ equals CARD9$^{-/-}$ (approximately $\\approx 5\\%$). LPS-induced TNF remains near wild-type across all CRISPR lines (e.g., $\\approx 80$–$100\\%$). Conclude the epistatic order Syk $\\to$ CARD9 $\\to$ MALT1.\n\nB. Create the same CRISPR single and double knockouts and stimulate exclusively with LPS at $100\\,\\text{ng}/\\text{mL}$ for $6$ hours to measure TNF by ELISA, expecting that Syk$^{-/-}$, CARD9$^{-/-}$, and MALT1$^{-/-}$ each reduce TNF to $\\leq 20\\%$ of wild-type and that double knockouts show further additive decreases. Infer order from the magnitude of TNF suppression under LPS.\n\nC. Create Syk$^{-/-}$, CARD9$^{-/-}$, and MALT1$^{-/-}$ single knockouts and analyze phagocytosis of fluorescent zymosan particles as a surrogate for CLR signaling. Predict that the Syk$^{-/-}$;CARD9^{-/-}$ double knockout shows an additive reduction relative to either single knockout, and use additivity versus non-additivity to order Syk, CARD9, and MALT1 in the pathway controlling TNF.\n\nD. Create Syk$^{-/-}$, CARD9$^{-/-}$, and MALT1$^{-/-}$ single knockouts and co-express a constitutively active Syk to test rescue. Predict that constitutively active Syk restores TNF in MALT1$^{-/-}$ cells to $\\geq 80\\%$ of wild-type upon curdlan stimulation, demonstrating that Syk is downstream of MALT1. Use lack of rescue in CARD9$^{-/-}$ cells to place CARD9 upstream of Syk.", "solution": "The problem statement is presented for validation and subsequent solution. The task is to identify the experimental design and expected results that would correctly map the functional order of three proteins—Spleen tyrosine kinase (Syk), Caspase Recruitment Domain containing protein 9 (CARD9), and Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1)—in the Dectin-1 signaling pathway leading to Tumor Necrosis Factor (TNF) production.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n\n*   **Receptor and Pathway:** A C-type lectin receptor (CLR) such as Dectin-1 on myeloid cells signals through a hem-immunoreceptor tyrosine-based activation motif (hemITAM).\n*   **Signaling Cascade:** The pathway involves recruitment of Syk, assembly of the CARD9–B-cell lymphoma/leukemia 10 (Bcl10)–MALT1 scaffold, activation of Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB), and induction of TNF.\n*   **Objective:** Map the order of function of Syk, CARD9, and MALT1 in CLR-induced TNF production.\n*   **Methodology:** Use Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) knockouts in a human monocyte-like cell line.\n*   **Stimulus and Readout:** Stimulate cells with a selective Dectin-1 agonist to trigger CLR signaling and quantify TNF output.\n*   **Foundational Bases:**\n    1.  **Linear Signaling Pathway Definition:** A proximal receptor-proximal kinase triggers downstream scaffolds and effectors that converge on transcriptional activation.\n    2.  **Principle of Genetic Epistasis:** For a linear pathway $X \\to Y$, the double mutant $X^{-/-};Y^{-/-}$ exhibits the phenotype of the $Y^{-/-}$ mutant when stimulated.\n    3.  **Central Dogma:** DNA $\\to$ RNA $\\to$ protein, linking signaling to transcription and translation of TNF.\n*   **Controls:** Appropriate controls must distinguish pathway specificity from global defects.\n\n**Step 2: Validate Using Extracted Givens**\n\n*   **Scientific Grounding:** The problem is firmly grounded in established principles of immunology and molecular cell biology. The Dectin-1 signaling pathway is a well-studied example of innate immune recognition. The components (Syk, CARD9, MALT1) are correctly placed within this pathway context. The use of CRISPR for generating knockouts and genetic epistasis analysis to order pathway components is a standard, robust, and valid scientific methodology. The problem is scientifically realistic and factually sound.\n*   **Well-Posedness:** The problem is well-posed. It asks for a specific experimental design to determine the order of three components in a defined pathway. The provided principle of genetic epistasis is the precise logical tool required to solve the problem, ensuring that a unique and meaningful solution exists.\n*   **Objectivity:** The problem is stated in precise, objective, and technical language, free from ambiguity or subjective claims. Terms like \"Dectin-1 agonist,\" \"CRISPR knockouts,\" and \"genetic epistasis\" have clear, universally understood meanings in the field.\n*   **Completeness and Consistency:** The problem is self-contained. It provides all necessary information: the pathway, the components, the goal, and the fundamental principle (epistasis) needed for the logical deduction. There are no internal contradictions.\n*   **Relevance:** The problem is directly relevant to the topic of *C-type lectin receptor signaling* in *immunology*.\n\n**Step 3: Verdict and Action**\n\nThe problem statement is valid. It is scientifically sound, well-posed, objective, and presents a non-trivial but solvable problem in experimental design based on fundamental biological principles. I will proceed with the solution.\n\n### Solution Derivation\n\nThe core of the problem lies in the correct application of the principle of genetic epistasis to a linear signaling pathway. The problem posits a pathway for CLR-induced TNF production and asks to confirm the order Syk $\\to$ CARD9 $\\to$ MALT1.\n\nThe principle of epistasis states that if two genes function in the same linear pathway, the phenotype resulting from the loss of function of both genes will be identical to the phenotype resulting from the loss of function of the gene that acts more downstream.\n\nLet us apply this rule to the hypothesized order: Syk $\\to$ CARD9 $\\to$ MALT1.\n1.  **Interaction between Syk and CARD9:** Since CARD9 is downstream of Syk, the phenotype of the double-knockout $Syk^{-/-};CARD9^{-/-}$ cell line must be the same as the phenotype of the single-knockout $CARD9^{-/-}$ cell line.\n2.  **Interaction between CARD9 and MALT1:** Since MALT1 is downstream of CARD9, the phenotype of the double-knockout $CARD9^{-/-};MALT1^{-/-}$ cell line must be the same as the phenotype of the single-knockout $MALT1^{-/-}$ cell line.\n3.  **Interaction between Syk and MALT1:** Since MALT1 is downstream of Syk, the phenotype of the double-knockout $Syk^{-/-};MALT1^{-/-}$ cell line must be the same as the phenotype of the single-knockout $MALT1^{-/-}$ cell line.\n\nIn all cases, the \"phenotype\" is the level of TNF secreted upon stimulation with a specific Dectin-1 agonist (e.g., curdlan). Since all three components—Syk, CARD9, and MALT1—are essential for the pathway, we expect that each single knockout ($Syk^{-/-}$, $CARD9^{-/-}$, $MALT1^{-/-}$) will lead to a severe reduction or complete ablation of TNF production compared to wild-type (WT) cells.\n\nAn essential component of a rigorous experiment is a specificity control. The signaling defect should be specific to the Dectin-1 pathway. A parallel pathway that also induces TNF, such as the Toll-like receptor 4 (TLR4) pathway activated by lipopolysaccharide (LPS), should remain largely intact in these knockout cells. If TNF production via the LPS-TLR4 pathway were also ablated, it would suggest a general defect in the cell's ability to produce TNF, rather than a specific signaling defect.\n\nWith these principles established, we evaluate the given options.\n\n### Option-by-Option Analysis\n\n**A. Create single knockouts Syk$^{-/-}$, CARD9$^{-/-}$, and MALT1$^{-/-}$, and double knockouts Syk$^{-/-}$;CARD9$^{-/-}$, Syk$^{-/-}$;MALT1$^{-/-}$, and CARD9$^{-/-}$;MALT1^{-/-}$ in the same parental background. Stimulate with curdlan at $100\\,\\mu\\text{g}/\\text{mL}$ for $6$ hours and quantify secreted TNF by enzyme-linked immunosorbent assay (ELISA), normalizing to wild-type set at $100\\%$. Include lipopolysaccharide (LPS, Toll-like receptor $4$ ligand, $100\\,\\text{ng}/\\text{mL}$) as a pathway specificity control. Predicted pattern under curdlan: each single knockout markedly reduces TNF (e.g., Syk $\\approx 10\\%$, CARD9 $\\approx 5\\%$, MALT1 $\\approx 5\\%$). Any double knockout that includes MALT1 equals MALT1$^{-/-}$ (approximately $\\approx 5\\%$), and Syk$^{-/-}$;CARD9^{-/-}$ equals CARD9$^{-/-}$ (approximately $\\approx 5\\%$). LPS-induced TNF remains near wild-type across all CRISPR lines (e.g., $\\approx 80$–$100\\%$). Conclude the epistatic order Syk $\\to$ CARD9 $\\to$ MALT1.**\n\n*   **Experimental Design:** This option proposes the correct set of experiments. It generates all necessary single and double knockouts. It uses a specific Dectin-1 agonist (curdlan) to activate the pathway of interest and a relevant readout (TNF protein by ELISA). Crucially, it includes an LPS stimulation as a specificity control to ensure the observed defects are specific to the CLR pathway. This design is comprehensive and rigorous.\n*   **Predicted Outcomes:** The predicted pattern of results perfectly aligns with the principle of genetic epistasis for the linear pathway Syk $\\to$ CARD9 $\\to$ MALT1.\n    *   $Syk^{-/-};CARD9^{-/-}$ phenotype equals $CARD9^{-/-}$ phenotype, placing CARD9 downstream of Syk.\n    *   $Syk^{-/-};MALT1^{-/-}$ phenotype equals $MALT1^{-/-}$ phenotype, placing MALT1 downstream of Syk.\n    *   $CARD9^{-/-};MALT1^{-/-}$ phenotype equals $MALT1^{-/-}$ phenotype, placing MALT1 downstream of CARD9.\n    *   The intact LPS response confirms pathway specificity.\n*   **Verdict:** **Correct**. This option describes a flawless experimental design and correctly interprets the results according to the foundational principle of genetic epistasis.\n\n**B. Create the same CRISPR single and double knockouts and stimulate exclusively with LPS at $100\\,\\text{ng}/\\text{mL}$ for $6$ hours to measure TNF by ELISA, expecting that Syk$^{-/-}$, CARD9$^{-/-}$, and MALT1$^{-/-}$ each reduce TNF to $\\leq 20\\%$ of wild-type and that double knockouts show further additive decreases. Infer order from the magnitude of TNF suppression under LPS.**\n\n*   **Experimental Design:** This option is fundamentally flawed. The objective is to map the Dectin-1 (CLR) pathway. Stimulating with LPS activates the TLR4 pathway, not the Dectin-1 pathway. While there might be some crosstalk, one cannot perform an epistasis analysis of the CLR pathway without activating it.\n*   **Predicted Outcomes:** The prediction that these knockouts would significantly reduce LPS-induced TNF is questionable, as these components are central to the CLR pathway, not the canonical TLR4-MyD88 pathway. Furthermore, expecting additive decreases contradicts the principle of epistasis for a linear pathway, which predicts the phenotype of the downstream mutant, not additivity.\n*   **Verdict:** **Incorrect**. The stimulus is wrong for the question being asked, and the interpretation of genetic interactions is flawed.\n\n**C. Create Syk$^{-/-}$, CARD9$^{-/-}$, and MALT1$^{-/-}$ single knockouts and analyze phagocytosis of fluorescent zymosan particles as a surrogate for CLR signaling. Predict that the Syk$^{-/-}$;CARD9^{-/-}$ double knockout shows an additive reduction relative to either single knockout, and use additivity versus non-additivity to order Syk, CARD9, and MALT1 in the pathway controlling TNF.**\n\n*   **Experimental Design:** This option uses an inappropriate readout. The question is explicitly about the pathway for *TNF production*. Phagocytosis is a different cellular function. While it may also be regulated by Dectin-1 and Syk, it is not guaranteed to follow the same linear Syk $\\to$ CARD9 $\\to$ MALT1 $\\to$ NF-κB axis that controls transcription. It is a poor surrogate for TNF induction.\n*   **Predicted Outcomes:** The prediction of an *additive* effect for a double knockout in a linear pathway is incorrect. Additivity suggests that genes operate in parallel pathways. The principle of epistasis states that for a linear pathway, the double mutant phenocopies the downstream single mutant.\n*   **Verdict:** **Incorrect**. The choice of readout is invalid for the specific question, and the predicted genetic interaction (additivity) is logically inconsistent with the premise of a linear pathway.\n\n**D. Create Syk$^{-/-}$, CARD9$^{-/-}$, and MALT1$^{-/-}$ single knockouts and co-express a constitutively active Syk to test rescue. Predict that constitutively active Syk restores TNF in MALT1$^{-/-}$ cells to $\\geq 80\\%$ of wild-type upon curdlan stimulation, demonstrating that Syk is downstream of MALT1. Use lack of rescue in CARD9$^{-/-}$ cells to place CARD9 upstream of Syk.**\n\n*   **Experimental Design:** This option describes a rescue experiment, which is another valid genetic tool. However, the logic applied is inverted.\n*   **Logic of Rescue:** In a linear pathway $A \\to B \\to C$, a constitutively active (c.a.) form of an upstream component (e.g., c.a. $A$) cannot bypass a downstream block (e.g., in a $B^{-/-}$ mutant). Conversely, a c.a. form of a downstream component (e.g., c.a. $B$) can function even if an upstream component is missing (e.g., in an $A^{-/-}$ mutant).\n*   **Analysis of Prediction:** The option predicts that c.a. Syk rescues the $MALT1^{-/-}$ phenotype. If the true order is Syk $\\to ... \\to$ MALT1, the signal from c.a. Syk would be blocked by the absence of the downstream component MALT1. Therefore, rescue should *not* occur. The predicted rescue would incorrectly imply that Syk is downstream of MALT1. The option's conclusion \"demonstrating that Syk is downstream of MALT1\" is based on this flawed prediction. Similarly, the statement \"Use lack of rescue in $CARD9^{-/-}$ cells to place CARD9 upstream of Syk\" is also logically inverted. Lack of rescue by c.a. Syk in $CARD9^{-/-}$ cells demonstrates that CARD9 is *downstream* of Syk.\n*   **Verdict:** **Incorrect**. The reasoning and interpretation of the rescue experiment are fundamentally wrong.\n\nIn summary, only option A presents a scientifically rigorous, logically sound experimental design and interpretation based on the principles provided.", "answer": "$$\\boxed{A}$$", "id": "2838106"}, {"introduction": "Beyond mapping the components of a pathway, a key goal of systems immunology is to quantitatively model its behavior. This practice introduces the Hill equation, a fundamental mathematical tool used to describe the \"switch-like\" or ultrasensitive input-output relationships common in signaling cascades. You will apply this model to calculate how a change in the activity of an upstream kinase, Spleen tyrosine kinase (Syk), translates into a change in a downstream response, the nuclear translocation of NF-κB, providing insight into the quantitative nature of signal processing [@problem_id:2838091].", "problem": "C-type lectin receptors on myeloid cells couple to spleen tyrosine kinase (Syk) via immunoreceptor tyrosine-based activation motifs, leading to Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation and nuclear translocation of the p65 subunit. Assume that under steady ligand stimulation, the fraction of maximal nuclear p65 translocation, denoted by $A(S)$, is a deterministic function of the effective Syk catalytic activity $S$ and follows a Hill input-output relationship with Hill coefficient $n$ and half-activation constant $K$, a well-tested phenomenological model for ultrasensitive signaling:\n$$\nA(S) = \\frac{S^{n}}{K^{n} + S^{n}}.\n$$\nA pharmacological perturbation halves Syk activity from a baseline value $S_{0}$ to $S_{0}/2$. Define the fold change in nuclear p65 translocation as the ratio of the perturbed output to the baseline output, i.e., $F \\equiv \\dfrac{A(S_{0}/2)}{A(S_{0})}$. Under the assumption that the Hill coefficient is $n=2$, derive a closed-form expression for $F$ in terms of $S_{0}$ and $K$, simplified as far as possible. Express your final answer as a single analytic expression. No rounding is required and no units should be included in the final expression.", "solution": "The problem statement is first subjected to validation.\n\nStep 1: Extract Givens.\nThe givens are:\n- The fraction of maximal nuclear p65 translocation is given by the function $A(S)$.\n- The input variable is the effective Syk catalytic activity, $S$.\n- The relationship between $A(S)$ and $S$ is the Hill equation: $A(S) = \\frac{S^{n}}{K^{n} + S^{n}}$.\n- The Hill coefficient is $n$.\n- The half-activation constant is $K$.\n- A perturbation changes the Syk activity from a baseline value $S_{0}$ to a perturbed value $S_{0}/2$.\n- The fold change in translocation is defined as the ratio $F \\equiv \\dfrac{A(S_{0}/2)}{A(S_{0})}$.\n- The Hill coefficient for this problem is specified as $n=2$.\n- The objective is to derive a closed-form expression for $F$ in terms of $S_{0}$ and $K$.\n\nStep 2: Validate Using Extracted Givens.\nThe problem is assessed for validity against the required criteria.\n- **Scientifically Grounded**: The problem is grounded in the field of systems biology and immunology. The Hill equation is a standard and widely accepted phenomenological model used to describe cooperative binding and ultrasensitive response in biochemical systems, including signaling pathways like the one described. The components (C-type lectin receptors, Syk, NF-κB) are correctly associated with myeloid cell signaling. Thus, the problem is scientifically sound.\n- **Well-Posed**: The problem is well-posed. All variables ($S_{0}$, $K$), parameters ($n=2$), and functions ($A(S)$) are explicitly defined. The quantity to be derived, $F$, is also unambiguously defined. The setup allows for the derivation of a unique, stable, and meaningful analytical solution.\n- **Objective**: The problem is stated using precise, objective, and formal language. It is free of ambiguity, subjectivity, or opinion-based claims.\n\nThe problem does not exhibit any of the flaws listed in the instructions (e.g., scientific unsoundness, incompleteness, contradiction, etc.). It is a standard exercise in mathematical modeling of biological systems.\n\nStep 3: Verdict and Action.\nThe verdict is that the problem is **valid**. A solution will be derived.\n\nThe derivation proceeds as follows.\nThe fraction of maximal nuclear p65 translocation, $A(S)$, as a function of Syk catalytic activity $S$, is given by the Hill equation:\n$$\nA(S) = \\frac{S^{n}}{K^{n} + S^{n}}\n$$\nWe are given that the Hill coefficient is $n=2$. Substituting this value into the equation yields:\n$$\nA(S) = \\frac{S^{2}}{K^{2} + S^{2}}\n$$\nThe baseline output at the initial Syk activity $S_{0}$ is:\n$$\nA(S_{0}) = \\frac{S_{0}^{2}}{K^{2} + S_{0}^{2}}\n$$\nFollowing the pharmacological perturbation, the Syk activity is halved to $S_{0}/2$. The perturbed output is therefore:\n$$\nA(S_{0}/2) = \\frac{(S_{0}/2)^{2}}{K^{2} + (S_{0}/2)^{2}}\n$$\nSimplifying the expression for $A(S_{0}/2)$:\n$$\nA(S_{0}/2) = \\frac{S_{0}^{2}/4}{K^{2} + S_{0}^{2}/4}\n$$\nTo clear the fraction in the denominator, we multiply the numerator and the denominator of the main fraction by $4$:\n$$\nA(S_{0}/2) = \\frac{4 \\times (S_{0}^{2}/4)}{4 \\times (K^{2} + S_{0}^{2}/4)} = \\frac{S_{0}^{2}}{4K^{2} + S_{0}^{2}}\n$$\nThe fold change, $F$, is defined as the ratio of the perturbed output to the baseline output:\n$$\nF = \\frac{A(S_{0}/2)}{A(S_{0})}\n$$\nSubstituting the derived expressions for $A(S_{0}/2)$ and $A(S_{0})$:\n$$\nF = \\frac{\\frac{S_{0}^{2}}{4K^{2} + S_{0}^{2}}}{\\frac{S_{0}^{2}}{K^{2} + S_{0}^{2}}}\n$$\nWe can simplify this complex fraction by multiplying by the reciprocal of the denominator:\n$$\nF = \\frac{S_{0}^{2}}{4K^{2} + S_{0}^{2}} \\times \\frac{K^{2} + S_{0}^{2}}{S_{0}^{2}}\n$$\nThe term $S_{0}^{2}$ appears in the numerator of the first fraction and the denominator of the second fraction, and thus cancels out, provided $S_{0} \\neq 0$. The case $S_{0}=0$ corresponds to zero baseline activity and zero translocation, for which the fold change is undefined, so we assume $S_{0} > 0$.\n$$\nF = \\frac{K^{2} + S_{0}^{2}}{4K^{2} + S_{0}^{2}}\n$$\nThis is the final expression for the fold change $F$ in terms of the baseline Syk activity $S_{0}$ and the half-activation constant $K$. The expression is in its simplest form.", "answer": "$$\\boxed{\\frac{K^{2} + S_{0}^{2}}{4K^{2} + S_{0}^{2}}}$$", "id": "2838091"}]}